- Pyramid Pharma Services has entered a five-year commercial supply agreement to manufacture an siRNA injectable therapy for a rare genetic kidney disease.
- The CDMO will provide sterile fill-finish services from its California facility, supported by recent infrastructure and automation investments.
Pyramid Pharma Services has entered into a five-year commercial supply agreement with a global pharmaceutical company to support the manufacture of a small interfering RNA (siRNA) injectable therapy for a rare genetic kidney disease. The U.S.-based CDMO will deliver sterile fill-finish contract manufacturing services from its facility in California to support global supply of the therapy.
The agreement positions Pyramid Pharma Services as a commercial manufacturing partner for injectable therapies, covering sterile fill-finish production as well as integrated drug product services such as device assembly, labeling, and packaging. The company said the partnership will support continued global availability of the therapy.
The announcement follows recent U.S. Food and Drug Administration (FDA) and customer inspections of Pyramid’s expanded manufacturing site in Costa Mesa, California. The expansion included investments in sterile manufacturing infrastructure, including a high-speed Groninger fill-finish line and increased automation for auto-injector device assembly.
According to the company, these upgrades are designed to enhance commercial-scale manufacturing capacity and technical capabilities for complex injectable medicines. The investments also support Pyramid’s contract manufacturing offering for pharmaceutical companies requiring reliable supply of drug products.
“This agreement reflects the confidence global pharmaceutical innovators place in Pyramid’s recently expanded state-of-the-art facility in Costa Mesa, CA to deliver reliable commercial manufacturing services with the highest standards of quality and regulatory compliance.”
Dirk Lange, Chief Executive Officer of Pyramid Pharma Services
